ACXP has been approved for a $10 million cryptocurrency purchase limit, ENFN has launched a 10% cash allocation, and BKKT's custody volume has surged by 40%

According to BBX data, yesterday global listed companies made breakthrough progress in the fields of "financial diversification" and "compliance custody," with the core data as follows:

• $10 million cryptocurrency purchase plan: Acurx Pharmaceuticals (NASDAQ: $ACXP) board officially approved the allocation of $10 million for the purchase of Bitcoin yesterday. As a biopharmaceutical company, ACXP clearly stated that this move aims to leverage the anti-inflation properties of BTC to hedge against the depreciation risk of long-term R&D funding.

• 10% cash asset allocation: Enfusion (NYSE: $ENFN) announced an update to its financial guidelines, planning to allocate 10% of redundant cash on its balance sheet in batches to BTC and ETH. This financial software giant plans to use crypto assets to enhance the overall risk-adjusted return of its treasury.

• $5 million increase: Nature's Miracle (NASDAQ: $NMHI) confirmed the launch of its first $5 million Bitcoin strategic treasury plan yesterday, marking the formal acceptance of crypto assets as reserve currency by companies in the agricultural technology sector.

• 40% custody growth: Bakkt (NYSE: $BKKT) Q4 forecast data shows that its enterprise-level crypto asset custody scale has increased by 40% year-on-year. This reflects a significant increase in the reliance of non-native crypto companies on compliant third-party custody institutions when entering the market to purchase cryptocurrencies.